Bio-Rad Laboratories, Inc. (BIO) FinancialsBIOBio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. (BIO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinical Diagnostics, accounting for 61.3% of total sales, equivalent to $399.00M. Another important revenue stream is Life Science. Understanding this composition is critical for investors evaluating how BIO navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Bio-Rad Laboratories, Inc. maintains a gross margin of 53.12%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 11.15%, while the net margin is 57.05%. These profitability ratios, combined with a Return on Equity (ROE) of 3.11%, provide a clear picture of how effectively BIO converts its operational activities into shareholder value.

In the context of the broader market, BIO competes directly with industry leaders such as QGEN and GKOS. With a market capitalization of $10.16B, it holds a leading position in the sector. When comparing efficiency, BIO's gross margin of 53.12% stands against QGEN's 63.28% and GKOS's 81.67%. Such benchmarking helps identify whether Bio-Rad Laboratories, Inc. is trading at a premium or discount relative to its financial performance.

Bio-Rad reported a Q2 2026 revenue of $651 million, slightly down 0.1% year-over-year, but exceeding expectations by $27.01 million. The gross margin remains strong at 53.12%, indicating solid profitability despite challenges in certain segments.